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Editorial on the Research Topic
Molecular Pathology of HTLV-1
Human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus discovered. It is
estimated that 10–20 million people are infected worldwide by this oncogenic virus. About 5–10%
of HTLV-1-infected individuals are at risk of developing either a fatal malignancy, adult T-cell
leukemia (ATL), or a chronic progressive neuroinflammatory disease, called HTLV-associated
myelopathy/tropical spastic paraparesis (HAM/TSP). Both diseases are incurable at present.
Many issues concerning HTLV-1’s life cycle and pathobiology are still unsolved or controversial,
and new approaches for prognostic stratification of patients and eradication of HTLV-1 infection
are in high demand (Willems et al., 2017).
The present Research Topic is focused on the following themes:
1. Functional analyses and oncogenic potential of HTLV-1 regulatory proteins.
2. HTLV-1-associated diseases and new therapeutic developments.
FUNCTIONAL ANALYSES AND ONCOGENIC POTENTIAL OF
HTLV-1 REGULATORY PROTEINS
Baratella et al. discuss the possible role of HBZ in the progression toward HTLV-1-associated
diseases. One key finding of these authors is the exclusive cytoplasmic localization of HBZ in
cells from HAM/TSP patients, which is in striking contrast to its nuclear localization in ATL
cells. This finding suggests a correlation between HBZ’s intracellular compartmentalization and the
clinical outcome of HTLV-1 infection. The authors also propose that the cytoplasmic localization
of HBZ in PBMC of HAM/TSP patients could be exploited as a molecular marker of disease.
Kulkarni and Bangham Kulkarni and Bangham discuss the interplay between Tax and HBZ
as well the influence of micro-environmental changes on latency and reactivation kinetics of
the provirus. The authors present a comprehensive summary of factors that induce and inhibit
plus-and minus-strand transcription of the provirus and propose that the binding of the cellular
factor CTCF to the provirus produces abnormal chromatin loops, resulting in changes of cellular
gene expression and possibly favoring the development of ATL. A research article by Gazon et
al. sheds light on the long-standing hypothesis that Tax must be expressed in cycles to allow
cell survival (Yoshida, 1987). By analyzing viral expression in HTLV-1 infected individuals and
in sheep infected with bovine leukemia virus (BLV, a retrovirus closely related to HTLV-1 that
produces B-cell neoplasias), the authors provide evidence for alternating expression of the plus- and
minus proviral strands. They describe a model based on transient bursts of Tax-driven sense-strand
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transcription, followed by antisense RNA synthesis and silencing
of plus strand synthesis. This mechanism would allow cell
proliferation in the presence of a strong host immune response
against Tax. Tanaka and Matsuoka review the cellular targets of
HTLV infection in vivo focusing on the evidence indicating that
HTLV-1 infects hematopoietic stem cells (HSC) in vivo and that
HBZ influences early stages of hematopoietic cell differentiation
and induces infected progenitor cells to abnormally differentiate
into Treg-like T-cells. The authors also highlight the ability of
HBZ to affect cell turnover by inducing genomic instability
through upregulation of miR-17 and miR-21, which inhibit the
expression of OBFC2A, a single-stranded DNA-binding protein
that protects genome stability. Using affinity-tagged protein and
shotgun proteomics, Panfil et al. identified the UBR5 E3 ubiquitin
ligase as a novel binding partner of HBZ. The authors show
that this interaction results in HBZ ubiquitination. Interestingly,
UBR5 was found to be overexpressed in T leukemia/lymphoma
cell lines and during the later stage of T-cell transformation
in vitro, while loss of UBR5 decreased cellular proliferation,
suggesting a role for UBR5 in maintaining the proliferative
phenotype of transformed T-cells. Gazon et al. discuss the effects
of Tax and HBZ on the transcription factors AP-1, ATF/CREB,
and Maf and the contribution of these pathways to HTLV-1-
induced cellular transformation. The authors dissect the intricate
mechanisms of AP-1 pathway activation and propose that AP-1 is
activated in HTLV-1-infected T-cells through Tax-dependent and
Tax-independent mechanisms. Experimental evidence suggests
that HBZ interacts with all threemembers of the Jun family: while
sequestering c-Jun and JunB in HBZ-containing nuclear bodies,
it cooperates with JunD to enhance transcription of the 3′LTR
and hTERT. Several aspects of NF-κB pathway deregulation
mediated by Tax andHBZ are reviewed by Fochi et al. By focusing
on differences in the abilities of Tax-1/HBZ and their HTLV-2
homologs Tax-2/APH-2 to interact with host factors, the authors
summarize the distinct impacts of Tax and HBZ on NF-κB
deregulation and their effects in cell survival and proliferation. In
an investigation of the influence of themicroRNA network on the
turnover of HTLV-1 infected cells, Sharma et al. provide evidence
that HTLV-1 infection induces upregulation of miR-34a. Based
on their findings, the authors propose that high miR-34a levels
may provide a selective advantage to HTLV-1 infected cells in
vivo that persists during the transformation process. Recent
studies have shown that the p8 accessory protein of HTLV-1
induces T-cell conjugates and cellular conduits that may facilitate
virus transmission. Donhauser et al. have developed a novel
method based on flow cytometry for the automated quantitation
of p8 transfer between cells. Using this method in time course
experiments the authors show that p8 is rapidly transferred
between Jurkat T-cells and that actin polymerization affects this
process. Cavallari et al. present a review of the interactions
between mitochondria and proteins coded by HTLV-1 and
the human tumor viruses, Epstein-Barr virus (EBV), Kaposi’s
sarcoma-associated herpesvirus (KSHV), hepatitis viruses B
and C (HBV and HCV), and human papillomavirus (HPV).
The authors discuss how these interactions may contribute to
viral replication, persistence and transformation and how these
functions are connected to the crucial role of mitochondria in
cellular bioenergetics, apoptosis, innate immunity, and redox
balance.
CONTROLLING HTLV-1-ASSOCIATED
DISEASES
Tagaya and Gallo provide an insightful comparison of the
oncogenicity of HTLV-1, other human oncoviruses and
Helicobacter pylori. Interestingly, the lifetime risk to develop
a malignancy is markedly higher in patients infected with
HTLV-1—compared to EBV, KSHV, HBV, HCV, HPV, and H.
pylori. Furthermore, the oncogenic mechanism of HTLV-1
is more direct. These striking features of HTLV-1 are often
overlooked, possibly because of the low prevalence of the virus
in the US and Europe. Based on these considerations the authors
affirm the notion that this most carcinogenic virus deserves the
“leukemia” name. Based its high oncogenic potential, Gallo et al.
thus recommend to return to the virus’ original name, “Human
T-cell leukemia virus” in place of the more generic “Human
T-cell lymphotropic virus.”
Pasquier et al. discuss the difficulties in treating HTLV-1
patients and the current therapies available, in particular for ATL,
and provide a schematic representation of the two modes of
HTLV-1 transmission, i.e., through de novo by virus particles and
clonal expansion of cells harboring the provirus. Using a novel
in vitro assay, the authors screened an impressive number of
drugs, and showed for the first time that the acyclic nucleoside
phosphonates Adefovir dipivoxil and Tenofovir disporoxil are
much more effective at blocking HTLV-1 transmission compared
to the conventional nucleoside reverse transcriptase inhibitor
AZT. In their review, Marino-Merlo et al. provide an up-to-
date overview of recent efforts to understand the mechanisms
involved in current therapeutic regimens for ATL. Targeted
biological therapies for ATL are thoroughly described in the
prospective to find novel molecular targets in ATL therapy.
Based on the accumulated evidence, the authors point out
that the control of virus spread is a crucial aspect in ATL
therapy.
Yamagishi et al. provide an overview of the multiple genetic
and epigenetic aberrations that characterize in vivo HTLV-
1 infection in its initial stages, when both Tax and HBZ
are at work. The authors highlight the crucial, and apparent
transient role of Tax in shaping the host cell genome and
epigenome with the active, persistent role of HBZ, which further
potentiates initiation and progression to ATL and HTLV-1
associated diseases. Queiroz et al. investigated the inflammatory
response in HTLV-1 associated diseases and analyzed the relation
between the IFNG+874A/T polymorphism and the progression
of HTLV-1 infection to symptomatic disease. Patients carrying
the polymorphic allele showed significantly higher levels of IFN-
gamma than those carrying the wild-type allele, suggesting that
asymptomatic carriers with the T allele of IFNG+874A/T and a
high proviral load have a high probability of developing HTLV-
1 associated inflammatory diseases. Moodad et al. provide a
comprehensive review of the mouse models of ATL and HTLV-
I infection. Transgenic animals for Tax and HBZ, as well as
Frontiers in Microbiology | www.frontiersin.org 2 December 2018 | Volume 9 | Article 3069
Bertazzoni et al. Editorial: Molecular Pathology of HTLV-1
knock-outs for key cellular regulators provide useful models to
understand the role of viral and host genes in the development
of ATL. In addition, models based on xenografts and humanized
immune-deficient mice provide a valuable platform to test new
therapies against ATL.
An interesting newmurine preclinical ATLmodel is presented
in the original paper by Vicario et al.. The authors describe
experiments in which they injected an HTLV-1-immortalized T-
cell line either alone or together with normal primary fibroblasts
into NGS mice, and demonstrate that fibroblasts strongly
enhance HTLV-1 the growth of this cell line, which partly
recapitulates the in vivo pattern of the lymphoma variant of ATL.
This model may be useful to test novel therapeutic interventions
for the aggressive lymphoma subtype of ATL.
Enose-Akahata et al. review the role of Tax and HBZ in
the pathogenesis of HAM/TSP. They describe the infiltration of
HTLV-1-infected lymphocytes into the CNS and their chronic
release of Tax, which is capable of producing a neurotoxic effect
on the long axons of corticospinal tracts involved in progressive
neurological disease. It appears that HBZ expression is able
to confer a pro-inflammatory phenotype to infected T-cells, a
property that would position HBZ as an important factor in the
HAM/TSP disease process.
Sato et al. describe an analysis of 453 HAM/TSP patients
enrolled in the Japanese “AAM-net” registry. By measuring eight
candidate biomarkers in PBMCs, serum and cerebrospinal fluid
(CSF) samples, they demonstrate that the levels of neopterin
and CXCL10 in CSF represent valuable markers to discriminate
among rapid, slow and very slow progressors. Based on these
results, the authors propose new classification criteria for disease
activity which will aid in optimizing treatment.
Using an integrated ex vivo approach, Leal et al. show
that antiretroviral genes and HAM/TSP cluster in two distinct
“proviral/antiviral” classes, of which the TRIM5a/TRIM22/BST2
antiviral subset is selectively up-regulated by IFN-beta signaling
in HAM/TSP. These findings provide mechanistic evidence for
the in vivo immunovirological effect of IFN-β treatment in
HAM/TSP and identify novel biomarkers as well as possible
therapeutic targets.
CONLUDING REMARKS
Nearly 40 years of research have yielded important insights
into diverse aspects of the biology of HTLV-1 infection and
pathogenesis. Nevertheless, we are still quite far from deciphering
the complexity of its associated diseases. We hope that the broad
range of issues addressed in this Research Topic will provide
new perspectives and groundwork for future studies aimed at
unraveling HTLV-1 pathogenesis and lead to the development of
novel tools to eradicate the virus and its diseases.
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